Consumption of a high-fat diet during pregnancy changes the expression of cytochrome P450 in the livers of infant male mice

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 4, 2013, Pages 649-657

  Tajima, Masataka ^a,b   Ikarashi, Nobutomo ^a   Okaniwa, Takehiro ^a   Imahori, Yukari ^a   Saruta, Kanako ^a   Toda, Takahiro ^a   Ishii, Makoto ^a   Tanaka, Yoshikazu ^a   Machida, Yoshiaki ^a   Ochiai, Wataru ^a   Yamada, Harumi ^b   Sugiyama, Kiyoshi ^a  

^a HOSHI UNIVERSITY   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Cytochrome P450; High fat diet; Pharmacokinetics; Pregnane X receptor

Indexed keywords

CHOLESTEROL; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 2C; CYTOCHROME P450 2E; CYTOCHROME P450 3A; FATTY ACID; GLUCOSE; INTERLEUKIN 1BETA; LITHOCHOLIC ACID; PREGNANE X RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFANT; LIPID DIET; LIVER; LIVER CELL NUCLEUS; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREGNANCY; PROGENY; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE;

ANIMALS; ANIMALS, NEWBORN; BACTEROIDES FRAGILIS; CYTOCHROME P-450 ENZYME SYSTEM; DIET, HIGH-FAT; DNA, BACTERIAL; FECES; FEMALE; INTERLEUKIN-1BETA; LIVER; MALE; MICE; MICE, INBRED ICR; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTORS, STEROID; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876917874     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-01017     Document Type: Article

References (37)

1. Chang GQ, Gaysinskaya V, Karatayev O, Leibowitz SF. Maternal high-fat diet and fetal programming: increased proliferation of hypothalamic peptide-producing neurons that increase risk for overeating and obesity. J. Neurosci., 28, 12107-12119 (2008).
2. Gregorio BM, Souza-Mello V, Carvalho JJ, Mandarim-de-Lacerda CA, Aguila MB. Maternal high-fat intake predisposes nonalcoholic fatty liver disease in C57BL/6 offspring. Am. J. Obstet. Gynecol., 203, 495, e1-e8 (2010).
3. Srinivasan M, Katewa SD, Palaniyappan A, Pandya JD, Patel MS. Maternal high-fat diet consumption results in fetal malprogramming predisposing to the onset of metabolic syndrome-like phenotype in adulthood. Am. J. Physiol. Endocrinol. Metab., 291, E792-E799 (2006).
4. Tozuka Y, Kumon M, Wada E, Onodera M, Mochizuki H, Wada K. Maternal obesity impairs hippocampal BDNF production and spatial learning performance in young mouse offspring. Neurochem. Int., 57, 235-247 (2010).
5. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol., 38, 389-430 (1998).
6. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270, 414-423 (1994).
7. Cuciureanu M, Vlase L, Muntean D, Varlan I, Cuciureanu R. Grapefruit juice - Drug interactions: importance for pharmacotherapy. Rev. Med. Chir. Soc. Med. Nat. Iasi, 114, 885-891 (2010).
8. Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol. Drug Interact., 20, 195-217 (2004).
9. Mannel M. Drug interactions with St. John's wort: mechanisms and clinical implications. Drug Saf., 27, 773-797 (2004).
10. Holloway MG, Laz EV, Waxman DJ. Codependence of growth hormone-responsive, sexually dimorphic hepatic gene expression on signal transducer and activator of transcription 5b and hepatic nuclear factor 4alpha. Mol. Endocrinol., 20, 647-660 (2006).
11. Sakuma T, Endo Y, Mashino M, Kuroiwa M, Ohara A, Jarukamjorn K, Nemoto N. Regulation of the expression of two female-predominant CYP3A mRNAs (CYP3A41 and CYP3A44) in mouse liver by sex and growth hormones. Arch. Biochem. Biophys., 404, 234-242 (2002).
12. Wiwi CA, Gupte M, Waxman DJ. Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4alpha-deficient mice. Mol. Endocrinol., 18, 1975-1987 (2004).
13. Ghose R, Omoluabi O, Gandhi A, Shah P, Strohacker K, Carpenter KC, McFarlin B, Guo T. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci., 89, 57-64 (2011).
14. Yoshinari K, Takagi S, Yoshimasa T, Sugatani J, Miwa M. Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm. Res., 23, 1188-1200 (2006).
15. Dubois BN, O'Tierney-Ginn P, Pearson J, Friedman JE, Thornburg K, Cherala G. Maternal obesity alters feto-placental cytochrome P4501A1 activity. Placenta, 33, 1045-1051 (2012).
16. Tajima M, Ikarashi N, Imahori Y, Okaniwa T, Saruta K, Ishii M, Kusunoki Y, Kon R, Toda T, Ochiai W, Yamada H, Sugiyama K. Consumption of a high-fat diet during pregnancy decreases the activity of cytochrome P450 3a in the livers of offspring. Eur. J. Pharm. Sci., 47, 108-116 (2012).
17. Han LK, Kimura Y, Okuda H. Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. Int. J. Obes. Relat. Metab. Disord., 23, 174-179 (1999).
18. Park SH, Ko SK, Chung SH. Euonymus alatus prevents the hyperglycemia and hyperlipidemia induced by high-fat diet in ICR mice. J. Ethnopharmacol., 102, 326-335 (2005).
19. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal. Biochem., 150, 76-85 (1985).
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685 (1970).
21. Kim S, Jin Y, Choi Y, Park T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem. Pharmacol., 81, 1343-1351 (2011).
22. Quan HY, Baek NI, Chung SH. Licochalcone A prevents adipocyte differentiation and lipogenesis via suppression of peroxisome proliferator-activated receptor γ and sterol regulatory element-binding protein pathways. J. Agric. Food Chem., 60, 5112-5120 (2012).
23. Mantena SK, Vaughn DP, Andringa KK, Eccleston HB, King AL, Abrams GA, Doeller JE, Kraus DW, Darley-Usmar VM, Bailey SM. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem. J., 417, 183-193 (2009).
24. Toda T, Ohi K, Kudo T, Yoshida T, Ikarashi N, Ito K, Sugiyama K. Ciprofloxacin suppresses Cyp3a in mouse liver by reducing lithocholic acid-producing intestinal flora. Drug Metab. Pharmacokinet., 24, 201-208 (2009).
25. Toda T, Ohi K, Kudo T, Yoshida T, Ikarashi N, Ito K, Sugiyama K. Antibiotics suppress Cyp3a in the mouse liver by reducing lithocholic acid-producing intestinal flora. Yakugaku Zasshi, 129, 601-608 (2009).
26. Godfrey KM, Barker DJ. Fetal programming and adult health. Public Health Nutr., 4 (2B), 611-624 (2001).
27. Ravelli AC, van Der Meulen JH, Osmond C, Barker DJ, Bleker OP. Obesity at the age of 50 y in men and women exposed to famine prenatally. Am. J. Clin. Nutr., 70, 811-816 (1999).
28. Dostalek M, Court MH, Yan B, Akhlaghi F. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br. J. Pharmacol., 163, 937-947 (2011).
29. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int. J. Clin. Pharmacol. Ther., 37, 8-19 (1999).
30. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol. Pharmacol., 44, 707-715 (1993).
31. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab. Dispos., 35, 1687-1693 (2007).
32. Ashino T, Oguro T, Shioda S, Horai R, Asano M, Sekikawa K, Iwakura Y, Numazawa S, Yoshida T. Involvement of interleukin-6 and tumor necrosis factor alpha in CYP3A11 and 2C29 downregulation by Bacillus Calmette-Guerin and lipopolysaccharide in mouse liver. Drug Metab. Dispos., 32, 707-714 (2004).
33. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol., 4, 224-232 (2003).
34. Down MJ, Arkle S, Mills JJ. Regulation and induction of CYP3A11, CYP3A13 and CYP3A25 in C57BL/6J mouse liver. Arch. Biochem. Biophys., 457, 105-110 (2007).
35. Gnerre C, Blättler S, Kaufmann MR, Looser R, Meyer UA. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics, 14, 635-645 (2004).
36. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov., 1, 259-266 (2002).
37. Toda T, Ohi K, Kudo T, Yoshida T, Ikarashi N, Ito K, Sugiyama K. Antibiotics suppress Cyp3a in the mouse liver by reducing lithocholic acid-producing intestinal flora. Yakugaku Zasshi, 129, 601-608 (2009).